The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

INTRODUCTION: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years comp...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Blood Lymphat Cancer
المؤلفون الرئيسيون: Ujjani, Chaitra, Mato, Anthony, Hill, Brian T, Allan, John N, Lansigan, Frederick, Jacobs, Ryan, Skarbnik, Alan, Tuncer, Hande, Pagel, John, Brander, Danielle, Cheson, Bruce, Barr, Paul, Roeker, Lindsey E, Pu, Jeffrey, Shah, Nirav N, Goy, Andre, Schuster, Stephen J, Lamanna, Nicole, Sehgal, Alison, Tam, Constantine S, Shadman, Mazyar
التنسيق: Artigo
اللغة:Inglês
منشور في: Dove 2020
الموضوعات:
Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7473982/
https://ncbi.nlm.nih.gov/pubmed/32943973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S262592
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة